The impact of DDR gene alterations on cancer formation is important in patients with hereditary cancer syndromes such as germline BRCA1/2 pathologic mutation carriers who have a higher relative risk incidence of breast, ovarian, uterine, and pancreatic cancers. This evidence concerns the gene BRCA1 and Inherited cancer-predisposing syndrome.